Actively Recruiting

Phase Not Applicable
Age: 50Years +
All Genders
NCT06627894

Attenuating DEPression With Internet CBT to Slow Cognitive Decline in Older ICU Survivors(ADEPT-ICU)

Led by Indiana University · Updated on 2025-12-17

300

Participants Needed

2

Research Sites

241 weeks

Total Duration

On this page

Sponsors

I

Indiana University

Lead Sponsor

N

National Institute on Aging (NIA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Depression affects one-third of intensive care unit (ICU) survivors and represents a potentially modifiable target to slow cognitive decline and reduce the risk of Alzheimer's disease and related dementias (ADRD). Our multi-PI team proposes a two-arm RCT called ADEPT-ICU (Attenuating DEPression with Internet CBT to Slow Cognitive Decline in Older ICU Survivors), which will test the efficacy of an internet CBT intervention called Good Days Ahead (GDA) to reduce the burden of subjective cognitive decline (SCD) in older ICU survivors with moderate to severe depressive symptoms after ICU hospitalization.

CONDITIONS

Official Title

Attenuating DEPression With Internet CBT to Slow Cognitive Decline in Older ICU Survivors(ADEPT-ICU)

Who Can Participate

Age: 50Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 50 years of age and older
  • Admitted to intensive care for more than 48 hours
  • Able to understand and provide informed consent
  • Elevated depressive symptoms defined by PHQ-9 or PHQ-8 scores (≥10, or 5-9 with core symptoms of anhedonia or depressed mood)
  • Willing to participate in cognitive testing
  • Access to a telephone
  • Discharged to home or an independent or assisted living facility
  • Evidence of subjective cognitive decline, memory change in past 1-3 years, or low score on Montreal Cognitive Assessment adjusted for demographics
Not Eligible

You will not qualify if you...

  • Diagnosis of dementia or neurodegenerative disease before ICU stay or on anti-dementia medications
  • Diagnosis of severe mental illness such as bipolar disorder, schizophrenia, or schizoaffective disorder
  • Persistent psychotic symptoms after ICU stay
  • Recent or recurrent alcohol or substance use disorder
  • Life expectancy less than 1 year (e.g., terminal cancer, hospice care)
  • History of ischemic or hemorrhagic stroke, traumatic brain injury, or neurosurgery around ICU stay
  • Uncorrected vision or hearing impairments including legal blindness or deafness
  • Status post tracheostomy and unable to communicate
  • Currently incarcerated or on parole after ICU stay

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Eskenazi Hospital

Indianapolis, Indiana, United States, 46202

Actively Recruiting

2

IU Health Methodist Hospital

Indianapolis, Indiana, United States, 46202

Actively Recruiting

Loading map...

Research Team

B

Babar Khan, MD, MS

CONTACT

L

Lori Rawlings, RN, BSN

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here